AEGiS-Reuters: S.Africa's Gold Fields agrees workplace AIDS deal

Reuters, Ltd.Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
Click here to return to Reuters main menu


DonateNow


S.Africa's Gold Fields agrees workplace AIDS deal

Reuters NewMedia - Wednesday December 12, 2001


JOHANNESBURG, Dec 12 (Reuters) - South African miner Gold Fields Ltd , facing a growing AIDS crisis, said on Wednesday it had ratified a deal with unions to combat the disease that affects at least one in four of its 50,000 workers.

Gold Fields -- the country's second biggest gold producer -- said the agreed workplace AIDS programme was one of the most advanced in South Africa, which has more people living with the disease than any other country in the world.

About 25 percent of Gold Fields' total workforce was living with HIV-AIDS although at some of its mines this was as high as 30 percent, Gold Fields spokesman Willie Jacobsz said.

The full impact of the pandemic was projected to be felt in five years, when the disease would add $4 to $5 to the cost of each ounce of gold produced by the firm.

Gold Fields' AIDS programme centres on slowing down the spead of the deadly disease through education and awareness programmes and the promotion of condom use.

It also includes treatment of opportunistic diseases, management of sexually transmitted diseases and voluntary testing and counselling. There is no major role for life-prolonging antiretroviral drugs in the programme.

The agreement was signed with the National Union of Mineworkers, the United Associations of South Africa and the Mineworkers Union Solidarity.

AIDS affects companies' financially mainly through loss of productivity and workforce skills as well as absenteeism.

The company earlier this year estimated that, without intervention, the prevalence rate would reach 40 percent by 2009, lifting gold costs by $10 an ounce.
011212
RE011219


Copyright © 2001 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.   Contact Reuters.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .